Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ApoGraft for Prevention of aGvHD
NCT02828878Phase 2Unknown
- Sponsor
- Cellect Biotechnology Ltd.
- Start
- Jan 2017
- Primary completion
- Jul 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ApoGraft in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and 2 more (4 cohorts), sponsored by Cellect Biotechnology Ltd. Primary endpoint: Overall incidence, frequency and severity of adverse events (AEs) at 180 days. Status: unknown.
02
Drugs
ApoGraft
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02828878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828878.